Page last updated: 2024-09-05

etravirine and Cancer of Ovary

etravirine has been researched along with Cancer of Ovary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Choi, J; Chung, JS; Ha, JS; Jang, WB; Kim, JH; Kim, YJ; Kwon, SM; Lee, DH; Ly, TTG; Min, SH; Rethineswaran, VK; Van Le, TH; Yang, JS; Yun, J	1

Other Studies

1 other study(ies) available for etravirine and Cancer of Ovary

Article	Year
Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis. International journal of molecular sciences, 2022, Jan-15, Volume: 23, Issue:2 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mucoproteins; Neoplasm Metastasis; Nitriles; Oncogene Proteins; Ovarian Neoplasms; Paclitaxel; Proteolysis; Pyrimidines; Reverse Transcriptase Inhibitors; Xenograft Model Antitumor Assays	2022

Article

Year

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis.

International journal of molecular sciences, 2022, Jan-15, Volume: 23, Issue:2

Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mucoproteins; Neoplasm Metastasis; Nitriles; Oncogene Proteins; Ovarian Neoplasms; Paclitaxel; Proteolysis; Pyrimidines; Reverse Transcriptase Inhibitors; Xenograft Model Antitumor Assays

2022